Author:
Thompson J F,Man M,Johnson K J,Wood L S,Lira M E,Lloyd D B,Banerjee P,Milos P M,Myrand S P,Paulauskis J,Milad M A,Sasiela W J
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,Genetics,Molecular Medicine
Reference28 articles.
1. Gresser U, Gathof BS . Atorvastatin: Gold standard for prophylaxis of myocardial ischemia and stroke—comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies. Eur J Med Res 2004; 9: 1–17.
2. Shear CL, Franklin FA, Stinnett S, Hurley DP, Bradford RH, Chremos AN et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. Circulation 1992; 85: 1293–1303.
3. Maitland-van der Zee AH, Klungel OH, Stricker BHC, Verschuren WMM, Kastelein JJP, Leufkins HGM et al. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis 2002; 163: 213–222.
4. Kajinami K, Takekoshia N, Brousseau ME, Schaefer EJ . Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 2004; 177: 219–234.
5. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP, Ridker PM . Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004; 291: 2821–2827.
Cited by
190 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献